In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Rapid Micro Biosystems gets $60mm in equity financing

Executive Summary

Rapid Micro Biosystems Inc. (rapid microbial detection technology) raised $60mm in a late-stage equity financing co-led by first-time backers Bain Capital Life Sciences and Xeraya Capital, which were joined by another new investor Asahi Kasei Medical and returning shareholders Longitude Capital, Quaker Partners, TVM Capital, and Richard K. Mellon. According to the Form D, 11 investors participated. The company will use the funds for worldwide commercial expansion, operations, and product innovation.
Deal Industry
  • In Vitro Diagnostics
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies